Keywords: AZA; azathioprine; ADA; adalimumab; CYA; cyclosporine A; CYX; cyclophosphamide; ETN; etanercept; FK; tacrolimus; IFX; infliximab; IS; immunosuppressant; LFM; leflunomide; MMF; mycophenolate mofetil; MTX; methotrexate; RTX; rituximab; TAK; Takayasu's Arter
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: TNF Inhibitor; IBD Treatment; Patient Management; Inflammation; ADA; adalimumab; CD; Crohn's disease; IBD; inflammatory bowel disease; IFX; infliximab; IM; immunomodulator; IQR; interquartile range; TNF; tumor necrosis factor; UC; ulcerative colitis;
Keywords: MTX; methotrexate; TNF; tumor necrosis factor; IL; interleukin; CTLA4; cytotoxic T-lymphocyte antigen 4; IFX; infliximab; ADA; adalimumab; GLM; golimumab; CZP; certolizumab pegol; ETN; etanercept; TCZ; tocilizumab; ABA; abatacept; RTX; rituximab; UTK; ust
Keywords: ADA; adalimumab; AEs; adverse events; AZA; azathioprine; CI; confidence interval; Cy; cyclosporine; CNS; central nervous system; CS; corticosteroids; CYC; cyclophosphamide; CZP; certolizumab pegol; ePOST; Extrapulmonary Physician Organ Severity Tool; ETN;
Keywords: Anticorps; biothérapies; calprotectine fécale; maladie de Crohn; maladies inflammatoires; chroniques intestinales; rectocolite hémorragique; Antibodies; biotherapy; fecal calprotectin; Crohn's disease; intestinal inflammatory disease; ulcerative coliti
Keywords: biologic; cyclosporine; immunosuppressant; methotrexate; perioperative; psoriasis; psoriatic arthritis; tumor necrosis factor-alfa inhibitor; CI; confidence interval; IBD; inflammatory bowel disease; IFX; infliximab; IL; interleukin; MeSH; medical subject
Keywords: RA; rheumatoid arthritis; IFX; infliximab; ETN; etanercept; ADCC; antibody-dependent cellular cytotoxicity; CDC; complement-dependent cytotoxicity; CCP; cyclic citrullinated peptide; RF; rheumatoid factor; MMP-3; matrix-metalloproteinase-3; DAS28-ESR; dis
Keywords: Ulcerative Colitis; Infliximab; Accelerated Induction; AD; accelerated dosing; ASUC; acute severe ulcerative colitis; CRP; C-reactive protein; IBD; inflammatory bowel disease; IFX; infliximab; IQR; interquartile range; SD; standard dosing; TNF; tumor necr
Keywords: Drug; Response To Therapy; Prognostic Factor; Biomarker; ACT; Active Ulcerative Colitis Trials; ASCA; anti-Saccharomyces cerevisiae antibodies; ASUC; acute severe ulcerative colitis; CI; confidence interval; CRP; C-reactive protein level; CS; corticostero
Keywords: CD; Crohn's disease; Anti-TNF-α; anti-tumor necrosis factor-α; IFX; infliximab; PCDAI; Pediatric Crohn's Disease Activity Index; ATI; anti-infliximab-antibodies; PDAI; Perianal Crohn's Disease Activity Index; QoL; quality of life; UC; ulcerative colitis
Keywords: Remicade; Drug Holiday; Antidrug Antibody; Pharmacokinetics; ATI; antibodies to infliximab; CI; confidence interval; CRP; C-reactive protein; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IMM; immunomodulator; IR; infusion reaction;
Keywords: ADA; adalimumab; CD; Crohn disease; CDAI; Crohn's Disease Activity Index; CrI; credible interval; CZP; certolizumab pegol; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IL-12/23; interleukin 12/23; NAT; natalizumab; OR; odds ratio;
Keywords: A; absenteeism; ADA; adalimumab; CD; Crohn's disease; CPC; conventional proctocolectomy and Brooke ileostomy; CZP; certolizumab pegol; HPWAW; hours per week actually worked; HPWFP; productivity and hours per week fully productive; IBD; inflammatory bowel
Keywords: TNF; tumor necrosis factor; MRI; magnetic resonance imaging; CT; computerized tomography; PFT; pulmonary function test; LN; lymph node; CNS; central nervous system; IFX; infliximab; FEV1; forced expiratory volume in 1Â s; FVC; forced vital capacity; TLC;
Simple and ultra-fast recognition and quantitation of compounded monoclonal antibodies: Application to flow injection analysis combined to UV spectroscopy and matching method
Keywords: Bvz; bevacizumab; CS; control standard; ifx; infliximab; PCA; principal component analysis; QC; quality control; rtx; rituximab; SEN; sensitivity; SPE; specificity; trz; trastuzumab; Monoclonal antibody; Qualitative control; Quantitative control; Second d
Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease
Keywords: AC; anterior chamber; ADA; adalimumab; BCVA; best-corrected visual acuity; BD; Behçet disease; CME; cystoid macular edema; FA; fluorescein angiography; IFX; infliximab; IQR; interquartile range; SD; standard deviation; SUN; Standardization of Uveitis Nom
Bath-PUVA therapy improves impaired resting regulatory T cells and increases activated regulatory T cells in psoriasis
Keywords: aTreg; activated regulatory T cells; Foxp3; forkhead-box p3; IL; interleukin; non-Treg; non-suppressive regulatory T cells; PASI; Psoriasis Area and Severity Index; PUVA; psoralen plus ultraviolet light A; rTreg; resting regulatory T cells; Th17; interleu
Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: AÂ Meta-analysis
Keywords: Crohn's Disease; Biologics; Pharmacokinetics; Serum Drug Level; ADA; antidrug antibodies; CD; Crohn's disease; CI; confidence interval; CZP; certolizumab pegol; ELISA; enzyme-linked immunosorbent assay; HMSA; homogenous mobility shift assay; IBD; infl
Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease
Keywords: Biologics; Real-World Effectiveness; Database Analysis; Propensity Matching; ADA; adalimumab; aHR; adjusted hazard ratio; CD; Crohn's disease; CI; confidence interval; CZP; certolizumab pegol; IBD; inflammatory bowel disease; ICD-9; International Classi
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Keywords: Monoclonal Antibody Therapy; IBD; Inflammatory Bowel Disease; Intestinal Loss of Protein; CRP; C-reactive protein; IFX; infliximab; IQR; interquartile range; TNF; tumor necrosis factor; UC; ulcerative colitis;
Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
Keywords: Anti-Tumor Necrosis Factor; Inflammatory Bowel Disease; Anti-TNF Agent; Serology; Prognosis; VCAM; ASCA; anti-Saccharomyces cerevisiae antibodies; ATI; antibodies to infliximab; CD; Crohn's disease; CI; confidence interval; CRP; C-reactive protein;
Infliximab Plus Plasma Exchange Rescue Therapy in Kawasaki Disease
Keywords: BCG; Bacille de Calmette et Guérin; CAL; Coronary artery lesions; CRP; C-reactive protein; FC; Fractional change; IFX; Infliximab; IL; Interleukin; IVIG; Intravenous immunoglobulin; KD; Kawasaki disease; PE; Plasma exchange; TB; Tuberculosis; TNF; Tumor
Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease
Keywords: QoL; quality of life; IBD; inflammatory bowel disease; CD; Crohn's disease; UC; ulcerative colitis; PCDAI; Pediatric Crohn's Disease Activity Index; IFX; infliximab; CRP; C-reactive protein; ARCL; autoregressive cross-lagged model; Ï2; Chi-square; df; de
Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
Keywords: OR; odds ratio; HR; hazard ratio; CI; confidence interval; TNF; tumour necrosis factor; CDAI; Crohn's Disease Activity Index; IBD; inflammatory bowel disease; CRP; C-reactive protein; SD; standard deviation; IQR; interquartile range; IFX; infliximab.; Ada
Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease
Keywords: AZA; azathioprine; CAI; clinical activity index; CD; Crohn's disease; CDAI; Crohn's disease activity index; CI; confidence interval; GMT; geometric mean titer; HAI; hemagglutination inhibition; IFX; infliximab; IS; group immunosuppressive group; 6MP; 6-me
Original ResearchFull Report: Clinical-Alimentary TractCombination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Keywords: Tumor Necrosis Factor Inhibitors; Purine Antimetabolites; Biologic Treatment; AEs; adverse events; ATI; antibodies to infliximab; AZA; azathioprine; CI; confidence interval; CS; corticosteroid; IBDQ; Inflammatory Bowel Disease Questionnaire; IFX; inflixim
American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Keywords: ACG; American College of Gastroenterology; ADA; adalimumab; AZA; azathioprine; BSG; British Society of Gastroenterology; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CI; confidence interval; CZP; certolizumab pegol; ECCO; European Crohn's an
Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
Keywords: Ulcerative Colitis; Crohn's Disease; Treatment; Safety; Pregnancy; ADA; adalimumab; BCG; bacillus Calmette-Guérin; CZP; certolizumab pegol; ELISA; enzyme-linked immunosorbent assay; IBD; inflammatory bowel disease; IFX; infliximab; Ig; immunoglobulin;
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Keywords: Anti-TNF Agent; Decision Analysis; Failed Therapy; Algorithm; ADA; adalimumab; ATI; antibodies to infliximab; CT; computed tomography; ICER; incremental cost-effectiveness ratio; IFX; infliximab; QALY; quality-adjusted life-year; TNF; tumor necrosis facto
Long-term Outcome of Perianal Fistulizing Crohn's Disease Treated With Infliximab
Keywords: IBD Therapy; Perianal Disease; Inflammatory Bowel Disease; Tumor Necrosis Factor Antagonist; CD; Crohn's disease; CI; confidence interval; HR; hazard ratio; IFX; infliximab; IQR; interquartile range; PCD; perianal Crohn's disease; ROC; receiver operating
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease
Keywords: ADA; adalimumab; Ab; antibodies; IBD; inflammatory bowel disease; IFX; infliximab; Crohn's disease; Adverse event; Acute severe infusion reaction; Delayed reaction; Infliximab; Adalimumab;
Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model
Keywords: Inflammation; Anti-Tumor Necrosis Factor (TNF) Agent; Side Effect; Intestine; IBD; Complication; AZA; azathioprine; IFX; infliximab; NHL; non-Hodgkin's lymphoma; QALY; quality-adjusted life-years; SAE; serious adverse event; SEER; Surveillance, Epidemiolo
Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging
Keywords: Inflammatory Bowel Disease; Anti-TNF-α Agents; Abdominal Surgery; Abdominal Imaging; IFX; infliximab; IQR; interquartile range; MRI; magnetic resonance imaging; pfCD; perianal fistulizing Crohn's disease; TE; time to echo; TNF-α; tumor necrosis factor
Special ArticleReport of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Keywords: mAbs; monoclonal antibodies; IFX; infliximab; ADA; adalimumab; CZP; Certolizumab pegol; PNR; primary non response to anti-TNF agent; LOR; loss of response to anti-TNF agent; ATI; antibodies to infliximab; ATA; antibodies to adalimumab; FcγR; Fc gamma rec
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Keywords: ADA; adalimumab; CD; Crohn's disease; CI; confidence interval; CTZ; certolizumab pegol; IFX; infliximab; 6MP; 6-mercaptopurine; NHL; non-Hodgkin's lymphoma; RCT; randomized controlled trial; SD; standard deviation; SEER; Surveillance, Epidemiology & End R
Intravenous iron therapy restores functional iron deficiency induced by infliximab
Keywords: CDAI; Crohn's Disease Activity Index; CD; Crohn's disease; CRP; C-reactive protein; EPO; Erythropoietin; FeS; I.V. iron sucrose; Hb; Haemoglobin; IBD; Inflammatory Bowel Disease; IBDQ; Inflammatory Bowel Disease Questionnaire; IDRA; Iron deficiency relate
Medical Therapy for Refractory Pediatric Crohn's Disease
Keywords: ATI; human antibody to infliximab; AZA; azathioprine; CYA; cyclosporine A; IFX; infliximab; 6-MP; 6-mercaptopurine; MTX; methotrexate; PML; progressive multifocal leukoencephalopathy; RA; rheumatoid arthritis; TNF; tumor necrosis factor;
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α
Keywords: aa; amino acid; CHX; cycloheximide; Eta; etanercept; Ifx; infliximab; JNK; c-Jun NH2-terminal kinase; MAPK; mitogen-activated protein kinase; mTNF; transmembrane TNF-α; ROS; reactive oxygen species; Ser; serine; TACE; TNF-α converting enzyme; TNF; tumor